Application of the brace framework for benefit-risk assessment, communication, and evaluation of Pexidartinib

被引：0
|
作者：
Wang, Eric [1 ]
Dharmani, Charles [1 ]
Salas, Maribel [1 ]
机构：
[1] Daiichi Sankyo Inc, Tokyo, Japan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
333
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [21] Benefit-risk assessment conceptual framework for exposure to biologics during pregnancy
    Bozzi, Laura
    Jacobson, Melanie H.
    Yost, Emily
    Cafone, Joseph
    Sheahan, Anna
    Levitan, Bennett S.
    Nelson, Robert M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 529 - 529
  • [22] Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit-Risk Balance of Medicines
    Coplan, P. M.
    Noel, R. A.
    Levitan, B. S.
    Ferguson, J.
    Mussen, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 312 - 315
  • [23] The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies
    Radawski, Christine A.
    Hammad, Tarek A.
    Colilla, Susan
    Coplan, Paul
    Hornbuckle, Kenneth
    Freeman, Emily
    Smith, Meredith Y.
    Sobel, Rachel E.
    Bahri, Priya
    Arias, Ariel E.
    Bennett, Dimitri
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (12) : 1532 - 1539
  • [24] Benefit-risk assessment of acne therapies
    Seukeran, DC
    Eady, EA
    Cunliffe, WJ
    LANCET, 1997, 349 (9060): : 1251 - 1252
  • [25] Benefit-risk assessment of vaccination strategies
    Hanslik, Thomas
    Boelle, Pierre Yves
    M S-MEDECINE SCIENCES, 2007, 23 (04): : 391 - 398
  • [26] Methods of therapeutic benefit-risk assessment
    Moride, Yola
    Lynd, Larry
    Abenhaim, Lucien
    Moore, L.
    Kurz, Xavier
    Hartford, Craig
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S1 - S1
  • [27] A Bayesian Approach for Benefit-Risk Assessment
    Zhao, Yueqin
    Zalkikar, Jyoti
    Tiwari, Ram C.
    LaVange, Lisa M.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (04): : 326 - 337
  • [28] Benefit-Risk Assessment of Nonprescription Diclofenac
    Brass, Eric P.
    Swanson, Jessica
    Weisman, Steven M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 464 - 465
  • [29] A new framework to address challenges in quantitative benefit-risk assessment for medical products
    Fu, Bo
    Li, Xuefeng
    Scott, John
    He, Weili
    CONTEMPORARY CLINICAL TRIALS, 2020, 95
  • [30] Incorporation of a Benefit-Risk Assessment Framework Into the Clinical Overview of Marketing Authorization Applications
    Wolka, Anne
    Warner, Margaret
    Bullok, Kristin
    Wang, JuAn
    Radawski, Christine
    Noel, Rebecca
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (01) : 130 - 134
12345